GSK Plc's U.S.-listed shares surged Wednesday after the pharmaceutical firm boosted its long-term outlook and launched a $2.5 billion stock buyback on the back of optimism about sales of its new ...

GlaxoSmithKline has filed its new COPD triple therapy with the FDA a full 18 months early, giving it a much needed boost in its respiratory franchise. The once-daily, 'closed triple therapy ...

GSK has joined a lengthening list of companies that have paused diversity, equity, and inclusion (DEI) targets under pressure ...

The company’s two established vaccines continue to boost sales for GSK’s greater vaccine portfolio, with Bexsero crossing the $1 billion milestone in 2024 and Menveo adding 387 million euros ...

Bank of New York Mellon Corp grew its position in GSK plc (NYSE:GSK – Free Report) by 2.2% during the fourth quarter, ...

It has been about a month since the last earnings report for GSK (GSK). Shares have added about 8% in that time frame, outperforming the S&P 500. Will the recent positive trend continue leading up ...

Shares of GSK plc (NYSE:GSK – Get Free Report) have been given an average rating of “Moderate Buy” by the ten brokerages that are presently covering the firm, Marketbeat.com reports. Seven analysts ...

GSK is betting on AI to boost innovation for its pipeline as investor concerns cloud over the company's research-and-development productivity, but a balanced approach toward regulation is ...

Some investors rely on dividends for growing their wealth, and if you're one of those dividend sleuths, you might be intrigued to know that GSK plc (LON:GSK) is about to go ex-dividend in just ...

Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. UK drugmaker GSK is struggling to convince the market that it can deliver on its plans to refill its ...